Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Aurobindo Pharma clinical trials
The registry lists 35 studies whose lead sponsor is Aurobindo Pharma or one of 2 companies grouped under it. 1 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 15, 2026.
Keep track of what changes. Save the Aurobindo Pharma studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesRegistry sponsor names on this page
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Aurobindo Pharma.
- Acrotech Biopharma Inc.28 studies →Subsidiary
Something wrong?
- Aurobindo Pharma Ltd4 studiesSame company
Something wrong?
- Lannett Company, Inc.3 studies →Acquired — became part of Aurobindo Pharma, Jun 29, 2026 · source ↗
Something wrong?
Focus areas
Conditions Aurobindo Pharma leads ten or more studies in, by study count. A broader condition is left out when almost all its studies are already in a narrower one listed here.
Studies
Recruiting first, then most recently updated. Showing 35 of 35.
- Study to Evaluate the Pharmacokinetics and Safety of Pralatrexate in Patients With Advanced Solid Tumor or Hematological Malignancy and Either Normal Hepatic Function or Mild, Moderate, or Severe Hepatic ImpairmentRecruitingNCT07036133Phase 1
Sponsor listed in the registry: Acrotech Biopharma Inc.
- To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCLActive, not recruitingNCT06072131Phase 3
Sponsor listed in the registry: Acrotech Biopharma Inc.
- Establish the PK of Belinostat in Patients With Wild-type, Heterozygous, and Homozygous UGT1A1*28 GenotypesCompletedNCT02680795Phase 1
Sponsor listed in the registry: Acrotech Biopharma Inc.
- This Study is to Assess the Efficacy of Difamilast Ointment in Mild to Moderate Atopic Dermatitis(AD)CompletedNCT05608343Phase 3
Sponsor listed in the registry: Acrotech Biopharma Inc.
- A Open-label Study to Assess the Long-term Safety of Difamilast Ointment 1% in Mild to Moderate Atopic DermatitisCompletedNCT05571943Phase 3
Sponsor listed in the registry: Acrotech Biopharma Inc.
- Extension Study for Patients Who Had Not Met Criteria for Discontinuation in Previous Sponsored Belinostat TrialsCompletedNCT04184869Phase 1
Sponsor listed in the registry: Acrotech Biopharma Inc.
- A Study to Demonstrate Pharmacokinetic and Pharmacodynamic Biosimilarity Between HEC-Glargine and US-Lantus® in Healthy Male VolunteersCompletedNCT05248841Phase 1
Sponsor listed in the registry: Lannett Company, Inc. · First submitted before Lannett Company, Inc. became part of Aurobindo Pharma
- Pharmacodynamic Bioequivalence Study of Albuterol Sulfate Inhalation Aerosol, 0.09 mg Albuterol Base/ InhalationWithdrawnNCT05292976Phase 3
Sponsor listed in the registry: Aurobindo Pharma Ltd
- A Dose-Finding Study of Folotyn® (Pralatrexate Injection) Plus CHOP With Peripheral T-Cell Lymphoma (PTCL)CompletedNCT02594267Phase 1
Sponsor listed in the registry: Acrotech Biopharma Inc.
- Clinical Pharmacodynamic Bioequivalence Study of Beclomethasone Dipropionate 40 mcg INHCompletedNCT04051710Phase 3
Sponsor listed in the registry: Aurobindo Pharma Ltd
- Clinical Endpoint Bioequivalence Study of Adapalene Gel 0.1%WithdrawnNCT04329403Phase 3
Sponsor listed in the registry: Aurobindo Pharma Ltd
- Safety & Efficacy Study High Dose Evomela Injection for MA Conditioning in MM Patients With Autologous TransplantationCompletedNCT01660633Phase 2
Sponsor listed in the registry: Acrotech Biopharma Inc.
- PK Study on Ready-to-Use Injection (VSLI-RTU) 1 Vial & 3 Vial Formulation Marqibo® in Hematological Malignant PatientsStatus unknownNCT04243434Phase 1
Sponsor listed in the registry: Acrotech Biopharma Inc.
- Phase 1 Study of Fusilev® to Prevent or Reduce Mucositis in Patients With Non-Small Cell Lung Cancer Receiving Folotyn®WithdrawnNCT01820091Phase 1
Sponsor listed in the registry: Acrotech Biopharma Inc.
- Phase 1 Study of Fusilev to Prevent or Reduce Mucositis in Patients With Non-Hodgkin's Lymphoma Receiving FolotynWithdrawnNCT01789723Phase 1
Sponsor listed in the registry: Acrotech Biopharma Inc.
- To Evaluate the Safety, Activity and Pharmacokinetics of Marqibo in Children and Adolescents With Refractory CancerCompletedNCT01222780Phase 1
Sponsor listed in the registry: Acrotech Biopharma Inc.
- Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment RegistryCompletedNCT01110733
Sponsor listed in the registry: Acrotech Biopharma Inc.
- Study of Pralatrexate in Female Patients With Previously-treated Breast CancerCompletedNCT01118624Phase 2
Sponsor listed in the registry: Acrotech Biopharma Inc.
- Study of Pralatrexate & Gemcitabine With B12 & Folic Acid to Treat Relapsed/Refractory Lymphoproliferative MalignanciesCompletedNCT00481871Phase 1/2
Sponsor listed in the registry: Acrotech Biopharma Inc.
- MTD Study PXD-101 in Combination With Paclitaxel + Carboplatin in Chemotherapy-Naive Patients With Stage IV NSCLCCompletedNCT01310244Phase 1/2
Sponsor listed in the registry: Acrotech Biopharma Inc.
- Study of Pralatrexate in Patients With Relapsed or Refractory Cutaneous T-cell LymphomaCompletedNCT00554827Phase 1
Sponsor listed in the registry: Acrotech Biopharma Inc.
- Phase I Mass Balance, PK and Safety Study of 14C-Labeled Belinostat in Patients With Advanced CancerCompletedNCT01583777Phase 1
Sponsor listed in the registry: Acrotech Biopharma Inc.
- Phase 1/2 Study of VSLI Plus Rituximab in Patients With Relapsed and/or Refractory NHLCompletedNCT01851551Phase 1/2
Sponsor listed in the registry: Acrotech Biopharma Inc.
- Phase 1 Dose Finding Study of Belinostat for Treatment of Patients With Peripheral T-cell Lymphoma (PTCL)CompletedNCT01839097Phase 1
Sponsor listed in the registry: Acrotech Biopharma Inc.
- Study of Pralatrexate With Vitamin B12 and Folic Acid in Patients With Relapsed or Refractory Peripheral T-cell LymphomaCompletedNCT00364923Phase 2
Sponsor listed in the registry: Acrotech Biopharma Inc.
- Pralatrexate and Bexarotene in Patients With Relapsed or Refractory Cutaneous T-cell LymphomaCompletedNCT01134341Phase 1
Sponsor listed in the registry: Acrotech Biopharma Inc.
- PK Study of Melphalan HCL & Alkeran for Injection of MA Conditioning in MM Patients of Autologous TransplantationCompletedNCT00925782Phase 2
Sponsor listed in the registry: Acrotech Biopharma Inc.
- Study of Pralatrexate to Treat Advanced or Metastatic Relapsed Transitional Cell Carcinoma of the Urinary BladderCompletedNCT00722553Phase 2
Sponsor listed in the registry: Acrotech Biopharma Inc.
- Liposomal Vincristine Plus Dexamethasone in Patients With Relapsed or Refractory Acute Lymphoblastic LeukemiaCompletedNCT00144963Phase 1/2
Sponsor listed in the registry: Acrotech Biopharma Inc.
- Pharmacokinetic Study of Liposomal Vincristine in Patients With Malignant Melanoma & Hepatic DysfunctionCompletedNCT00145041Phase 1
Sponsor listed in the registry: Acrotech Biopharma Inc.
- To Evaluate Safety and Pharmacokinetics of Belinostat in Patients Who Have Mild, Moderate and Severe Renal Impairment.TerminatedNCT02679131Phase 1
Sponsor listed in the registry: Acrotech Biopharma Inc.
- Phase II Study of Folotyn With Leucovorin to Prevent/Reduce Mucositis in Patients With Hematological MalignanciesCompletedNCT02106650Phase 2
Sponsor listed in the registry: Acrotech Biopharma Inc.
- Steady State Global Bioequivalence Study of Amphotericin B Liposome for Injection 50 mg/ Vial in Fed ConditionCompletedNCT03636659Phase 1
Sponsor listed in the registry: Aurobindo Pharma Ltd
- Topical Application of Cocaine HCl 4%, or 10%, or Placebo Solution in Local (Topical) AnesthesiaCompletedNCT02500836Phase 3
Sponsor listed in the registry: Lannett Company, Inc. · First submitted before Lannett Company, Inc. became part of Aurobindo Pharma
- Topical Application of Cocaine HCl 4% and 10% on Safety and Efficacy in Local (Topical) AnesthesiaTerminatedNCT01746940Phase 3
Sponsor listed in the registry: Lannett Company, Inc. · First submitted before Lannett Company, Inc. became part of Aurobindo Pharma